OOIR: Observatory of International Research

Papers

(The TQCC of Future Oncology is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)

Article	Citations
Spectrum of Lymphoma Subtypes Based on the Latest World Health Organization Classification in Southern Iran from 2000 to 2011	101
Bidirectional Deep Neural Networks to Integrate RNA and DNA Data for Predicting Outcome for Patients with Hepatocellular Carcinoma	81
Patient Preferences for Advanced Hepatocellular Carcinoma Treatment: A Multicountry Stated Preference Study	78
A Concise Prognostic Score System for Diffuse Large B-Cell Lymphoma: A Retrospective Study with Long-Term Follow-Up	72
Urothelial Carcinoma in COVID-19: Lessons From a Pandemic and Their Impact on Clinical Practice	65
Phase II trial of niraparib for BRCA -mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B	53
OPERA: a phase II trial of oregovomab plus non-platinum chemotherapy in PARP inhibitor/platinum-resistant ovarian cancer	49
Association of Facility Type With Overall Survival in Patients with Nonsurgically Managed Pancreatic Cancer	44
A Plain Language Summary of the ASCENT Study: Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer	43
Nomogram Predicting Prostate Cancer in Patients with Negative Prebiopsy Multiparametric Magnetic Resonance	41
Psychometric Properties of the 37-Item Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) scale	39
An observational study of hospitalized COVID-19 patients with cancer in San Diego county	37
Should One Use the Combination of Abiraterone and Poly(ADP-ribose) Polymerase Inhibitors as First-Line Therapy for all Patients with Metastatic Castration-Resistant Prostate Cancer?	36
Efficacy and Safety of Darolutamide in Black/African–American Patients from the Phase III ARAMIS Study	36
Cutaneous Adverse Events Associated with PD-1 Inhibitor-based Therapy in Patients with Non-Small-Cell Lung Cancer	36
Current Treatment Landscape of Pancreatic Cancer Patients in a Network of Office-based Oncologists in Germany	36
6 ^th Symposium on Primary Breast Cancer in Older Women	35
Integrating radium-223 therapy into the management of metastatic prostate cancer care: a plain language summary	35
Caregiver survey in glioblastoma focused on cognitive dysfunction: development and results from a multicenter study	32
From part to whole, operative link on to endoscopic grading of gastric intestinal metaplasia, pathology to endoscopy: gastric intestinal metaplasia graded by endoscopy	31
The BEETS (JACCRO CC-18) Trial: An Observational and Translational Study of BRAF -Mutated Metastatic Colorectal Cancer	31
Evidence from a meta-analysis for the prognostic and clinicopathological importance of DKC1 in malignancies	30
Prognostic Factors Affecting Infantile Medulloblastoma Outcomes in the Molecular Era: A 12-year Single-Center Experience from Egypt	30
miRNA-767 and its binding site polymorphism in the mTOR gene act as potential biomarkers for female reproductive cancers	29
Resveratrol and miR-200c: insights into the prevention of oral squamous cell carcinoma	29

Capecitabine Maintenance Therapy in Metastatic Colorectal Cancer Patients with no Evidence of Disease: CAMCO Trial	29
Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma	29
Brain Injury after Cranial Radiotherapy Combined with Immunotherapy for Brain Metastases in Lung Cancer: A Retrospective Study	28
Results of a survey study on health professionals’ perceptions of tumor boards in Brazil	28
The Effects of Managing Cancer and Living Meaningfully (CALM) on Psychological Distress in Esophageal Cancer Patients	28
Prediction model based on radiomics and clinical features for preoperative lymphovascular invasion in gastric cancer patients	27
Radiofrequency ablation versus stereotactic body radiation therapy for hepatocellular carcinoma: a meta-regression	26
The Power of Hope: Views of Ovarian Cancer Patients on How Maintenance Therapy Affects Their Lives (VOCAL)	26
Plain Language Summary of the Final Results from the GioTag Study	25
Sex bias phenomenon in oral cancer: an insight	25
Daratumumab in Indian Patients with Relapsed and Refractory Multiple Myeloma: A Prospective, Multicenter, Phase IV Study	25
Prognostication for Surgically Treated Papillary Renal Cell Carcinoma: Which Model is the Optimal Choice?	25
ADJUBIL: Phase II Study of Adjuvant Immunotherapy with STRIDE Regimen With/Without Capecitabine in Biliary Tract Cancers	25
Retrospective evaluation of safety and effectiveness of same-day pegfilgrastim in patients with lung cancer	24
Protocol of the Integrated Boost to the Dominant Intraprostatic Nodule in Stereotactic Body Radiation Therapy for Localized Prostate Cancer	24
Real-world febrile neutropenia rates with same-day versus next-day pegfilgrastim after myelosuppressive chemotherapy	24
First Advanced Course on Biomarkers in Molecular and Immuno-Oncology in the Middle East	23
Corrigendum	23
First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population	23
Clinical-Pathological Shrinkage Modes Could Help to Guide Breast-Conserving Surgery After Neoadjuvant Therapy	22
Treatment of muscle-invasive urothelial cancer with nivolumab (CheckMate 274 study): a plain language summary	22
Camrelizumab and metronomic capecitabine for patients with treatment-refractory solid tumors (McCREST trial)	22
Exploring Exosome Data to Identify Prognostic Gene Signatures for Lung Adenocarcinoma	21
Predicting Amplification of MYCN using CpG Methylation Biomarkers in Neuroblastoma	21
The effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes in patients with breast cancer	21
Frontline anti-PD-1/PD-L1 Versus Bevacizumab in Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis	21
Cabozantinib Plus Immunotherapy Combinations in Metastatic Renal Cell and Urothelial Carcinoma	20
The SYK inhibitor: a novel agent for improved outcomes in relapsed/refractory diffuse large B-cell lymphoma	20
Corrigendum	20
Trabectedin and radiotherapy in soft tissue sarcomas: friends or foes?	19
Expression of Interferon Regulatory Factor Family and its Prognostic value in Acute Myeloid Leukemia	19
Welcoming the 20th Volume of Future Oncology	19
Actual situation of decision-making support from medical staff when cancer patients make treatment choices	19
Outcomes of postoperative adjuvant transarterial chemoembolization for hepatocellular carcinoma according to the Ki67 index	18
Acalabrutinib and its use in the Treatment of Chronic Lymphocytic Leukemia	18
Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Breast Cancer: A Plain Language Summary of the DESTINY-Breast03 Study	18
Plain Language Summary of the CROWN Study Comparing Lorlatinib with Crizotinib for People with Untreated Non-Small Cell Lung Cancer	18
Direct Costs of Antineoplastic and Supportive Treatment for Progressive Multiple Myeloma in a Tax-Based Health System	18
Thoughts and Suggestions on the Fact That Dacomitinib Reduction did not Affect its Efficacy in the Archer 1050 Study	18
Systemic Therapy, Survival and End-Of-Life Costs for Metastatic Triple-Negative Breast Cancer: Retrospective SEER-Medicare Study of Women Age ≥65 Years	18
Polymorphism in miRNA Target Sites of CEP-63 and CEP-152 Ring Complex Influences Expression of CEP Genes and Favors Tumorigenesis in Gliom	18
Prognostic Value of Platelet Distribution Width and Mean Platelet Volume in Patients with Laryngeal Cancer	17
Sorafenib and Hepatocellular Carcinoma: is Alpha-Fetoprotein a Biomarker Predictive of Tumor Biology and Primary Resistance?	17
Can Pretreatment Blood Biomarkers Predict Pathological Response to Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer?	17
Incidence of safety events after immune checkpoint inhibitor initiation for advanced-stage non-small-cell lung cancer: a real-world study	17
Patients’ and oncologists’ preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer	17
Cost–effectiveness of Immune Checkpoint Inhibitors in the Treatment of Non-Small-Cell Lung Cancer as a Second Line in Taiwan	16
Highlights of the San Antonio Breast Cancer Symposium 2020: Part 1	16
Developing an Immune Signature for Triple-Negative Breast Cancer to Predict Prognosis and Immune Checkpoint Inhibitor Response	16
Genetic Interactions of Mitochondrial Sirtuins in Brain Tumorigenesis	16

Development of a model to predict the prognosis of esophageal carcinoma based on autophagy-related genes	16
A Phase III Trial of Neoadjuvant Intraperitoneal and Systemic Chemotherapy for Gastric Cancer with Peritoneal Metastasis	16
Real-world Outcomes with Second-Line Therapy in Advanced Esophageal Squamous Cell Carcinoma using SEER-Medicare Data	16
Stratification of Axillary Lymph Node Metastasis Risk with Breast MRI in Breast Cancer	16
New Landscapes in the Management of Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: Oral Decitabine	16
Immunotherapy for Liposarcoma: Emerging Opportunities and Challenges	15
Niraparib treatment for patients with BRCA -mutated ovarian cancer: review of clinical data and therapeutic context	15
Efficacy and Safety of Bevacizumab in Patients with Low-Grade Serous Ovarian Cancer	15
Podcast article: Biomarker testing in colorectal cancer	15
Efficacy and Tolerability of Current Treatments for Hormone-Refractory Prostate Cancer Patients with Visceral Metastases	15
Large-scale Omics Data Reveal the Cooperation of Mutation-circRNA-miRNA-Target Gene Network in Liver Cancer Oncogenesis	15
Achieving White Blood Cell Equity: Are the Safety Profiles of Biosimilar and Reference Pegfilgrastims Comparable?	15
The 7 ^th Symposium on Primary Breast Cancer in Older Women	15
Isatuximab for Relapsed/Refractory Multiple Myeloma: Review of Key Subgroup Analyses from the Phase III ICARIA-MM Study	15
Withdrawal of Dacomitinib Treatment due to Absence of Toxicities is not Justified	15
High PD-L1 Expression on Immune Cells, But not on Tumor Cells, is a Favorable Prognostic Factor in Urothelial Carcinoma	15
Real-World Efficacy of Docetaxel Plus Nintedanib After Chemo-Immunotherapy Failure in Advanced Pulmonary Adenocarcinoma	15
Clinical and Laboratory Outcomes of the Solid Cancer Patients Reinfected with SARS-CoV-2	15
Dedifferentiated Chondrosarcoma: Current Standards of Care	15
Novel Imaging Strategies for Prostate Cancer	15
Genetic Markers of Chronic Lymphocytic Leukemia: A Retrospective Study of 312 Patients from a Reference Center in Lebanon	15
The Implications from the Interplay of Neoadjuvant Chemoradiotherapy and the Immune Microenvironment in Rectal Cancer	15
Identification and Validation of a Hub Gene Prognostic Index for Hepatocellular Carcinoma	15
Real-World Symptoms, Disease Burden, Resource Use and Quality of Life in US Patients with Advanced Renal Cell Cancer	15
Oral Submucous Fibrosis and Heterogeneity in Outcome Measures: A Critical Viewpoint	15
Same-Day Versus Next-Day Pegfilgrastim or Pegfilgrastim-Cbqv in Patients with Lymphoma Receiving CHOP-Like Chemotherapy	14
Patient Satisfaction with Telemedicine for Prechemotherapy Evaluation During the COVID-19 Pandemic	14
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study)	14
Indications for and Contraindications of Immune Checkpoint Inhibitors in Cancer Patients with COVID-19 Vaccination	14
Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors	14
30 years of PI3K: an interview with Bart Vanhaesebroeck	14
Pembrolizumab for the treatment of advanced esophageal cancer	14
Targeted Therapy Moves to Earlier Stages of Non-Small-Cell Lung Cancer: Emerging Evidence, Controversies and Future Challenges	14
A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small-cell lung cancer	14
Systematic literature Review for the Association of Biomarkers with Efficacy of Anti-PD-1 Inhibitors in Advanced Melanoma	13
Is Obesity a Risk Factor in Cancer Patients with COVID-19?	13
Clinical protocol phase II study of tumor infiltrating lymphocytes in advanced tumors with alterations in the SWI/SNF complex: the TILTS study	13
Preclinical and phase I studies of an antisense oligonucleotide drug targeting IGF-1R in liver cancer	13
Systematic literature review and network meta-analysis of pembrolizumab versus other interventions for previously untreated, unresectable or metastatic, MSI-high or MMR-deficient CRC	13
Real-World Anticancer Medications for Reproductive-Age Women with Breast Cancer by Using a Claims Database in Japan	13
Association of Illness Perception with Chemotherapy-Induced Nausea and Vomiting: A Turkish Oncology Group (TOG) Study	13
STARBOARD: encorafenib + binimetinib + pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma	13
Expression Profiles and Prognostic Roles of m6A Writers, Erasers and Readers in Gastric Cancer	13
Cancer cytogenetics in the era of artificial intelligence: shaping the future of chromosome analysis	13
TRESBIEN (OGSG 2101): encorafenib, binimetinib and cetuximab for early recurrent stage II/III BRAF V600E-mutated colorectal cancer	13
A Phase III, Randomized, Open-Label Study (CONTACT-02) of Cabozantinib Plus Atezolizumab Versus Second Novel Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer	13
Platinum Ineligibility in Squamous Cell Carcinoma of the Head and Neck: Consensus from Central America and the Caribbean	13
Natural Orifice Specimen Extraction Surgery Versus Small-Incision Assisted Laparoscopic Radical Right Hemicolectomy	13
A Phase I Study of the Safety, Pharmacokinetics and Efficacy of Navitoclax Plus Docetaxel in Patients with Advanced Solid Tumors	13
Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study	13
Effects of Genetic Polymorphisms of LINC-PINT Gene on Liver Cancer Susceptibility in the Chinese Han Population	13
State of Cancer Care in India and Opportunities for Innovation	13
Quality-Adjusted Survival in Patients with Metastatic Colorectal Cancer Treated with Fruquintinib in the FRESCO Trial	13
A phase II trial of the super-enhancer inhibitor Minnelide™ in advanced refractory adenosquamous carcinoma of the pancreas	12
PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer	12
siRNA-Based Approaches for Castration-Resistant Prostate Cancer Therapy Targeting the Androgen Receptor Signaling Pathway	12
The relationship between VDR polymorphisms and keratinocyte carcinomas: a systematic review and meta-analysis	12
In -Class Transition from Bortezomib-Based Therapy to IRd is an Effective Approach in Newly Diagnosed Multiple Myeloma	12
Development and Validation of An Immune Gene Set-Based Prognostic Signature in Cutaneous Melanoma	12
Application of Cherenkov Radiation in Tumor Imaging and Treatment	12
Age-Dependent Prognostic Value of KRAS Mutation in Metastatic Colorectal Cancer	12
Role of Opiorphin Genes in Prostate Cancer Growth and Progression	12
Risk of Reactivation of Occult Hepatitis B During Immunotherapy in Cancer Treatment: Myth, Reality or New Horizons?	12
Clinical Activity and Safety of the Anti-PD-1 Monoclonal Antibody Dostarlimab for Patients with Recurrent or Advanced dMMR Endometrial Cancer	12
Anti-BRAF/Anti-MEK Targeted Therapies for Metastatic Melanoma Patients During the COVID-19 Outbreak: Experience from an Italian Skin Cancer Unit	12
KEYSTEP-008: Phase II Trial of Pembrolizumab-Based Combination in MSI-H/dMMR Metastatic Colorectal Cancer	12
Real-world treatment patterns and overall survival in BRAF -mutant melanoma patients treated with immunotherapy or targeted therapy	12
Venetoclax-Based Combinations for the Treatment of Newly Diagnosed Acute Myeloid Leukemia	11
Financial Toxicity and its Impact on Health Outcomes and Caregiver Burden Among Adult Cancer Survivors in the USA	11
Quality of Life Assessment in Renal Cell Carcinoma Phase II and III Clinical Trials Published between 2010 and 2020: a Systematic Review	11
CDK4/6 Inhibitors: Mechanisms of Resistance and Potential Biomarkers of Responsiveness in Breast Cancer	11
The prognostic value of radiomic features in liver-limited metastatic colorectal cancer patients from the TRIBE2 study	11
Preferences of Adults with Cancer for Systemic Cancer Treatment: Do Preferences Differ Based on Age?	11
Adjuvant EGFR Tyrosine Kinase Inhibitors for Patients with Resected EGFR -Mutated Non-Small-Cell Lung Cancer: A Network Meta-Analysis	11
Pregnancy and Perinatal Outcomes Following Exposure to Antineoplastic Agents Around Pregnancy within the US FDA Adverse Event Reporting System	11
Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia	11
The role of miRNAin prostate cancer diagnosis, prognosisand treatment response: a narrative review	11
Oncoplastic Breast-Conservative Surgery for Breast Cancers: A Uni-Institutional Case–Control Study	11
Neoadjuvant Osimertinib With/Without Chemotherapy Versus Chemotherapy Alone for EGFR -Mutated Resectable Non-Small-Cell Lung Cancer: NeoADAURA	11
GOBLET: a phase I/II study of pelareorep and atezolizumab +/- chemo in advanced or metastatic gastrointestinal cancers	11

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Limited-Stage Small-Cell Lung Cancer: A Meta-Analysis	11
Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design	10
Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib	10
Patterns of Colorectal Cancer Diagnosis Among Younger Adults in a Real-World, Population-Based Cohort	10
Treatment patterns and clinical outcomes in metastatic urothelial carcinoma: a German retrospective real-world analysis	10
Anemia-related response end points in myelofibrosis clinical trials: current trends and need for renewed consensus	10
Nivolumab in Gastric/Gastroesophageal Junction Cancer: Real-World Data from UK Early Access to Medicines Scheme	10
HERTHENA-Lung01: A Phase II Study of Patritumab Deruxtecan (HER3-DXd) in Previously Treated Metastatic EGFR -mutated NSCLC	10
Margetuximab in HER2-positive metastatic breast cancer	10
HERIZON-GEA-01: Zanidatamab + chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma	10
Pragmatic Patient Engagement in Designing Pragmatic Oncology Clinical Trials	10
Factors for Incidence Risk and Prognosis in Non-Small-Cell Lung Cancer Patients with Synchronous Brain Metastasis: A Population-Based Study	10
Development and validation of prognostic nomograms in patients with hepatocellular carcinoma: a population-based study	10
Cost–effectiveness of aumolertinib as first-line treatment for EGFR-mutated advanced nonsmall-cell lung cancer	9
DUART: Durvalumab After Radiotherapy in Patients with Unresectable, Stage III NSCLC who are Ineligible for Chemotherapy	9
Economic burden in US patients with newly diagnosed acute myeloid leukemia receiving intensive induction chemotherapy	9
Logistical challenges of CAR T-cell therapy in non-Hodgkin lymphoma: a survey of healthcare professionals	9
Single-Dose Netupitant/Palonosetron Versus 3-day Aprepitant for Preventing Chemotherapy-Induced Nausea and Vomiting: A Pooled Analysis	9
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer	9
A perioperative study of Safusidenib in patients with IDH1 -mutated glioma	9
Diagnosis of chondrosarcoma in a noninvasive way using volatile organic compounds in exhaled breath: a pilot study	9
Crosstalk Between Circrnas and the PI3K/AKT and/or MEK/ERK Signaling Pathways in Digestive Tract Malignancy Progression	9
Prostate-specific antigen and health-related quality of life in individuals with advanced prostate cancer treated with apalutamide: a plain language summary of the SPARTAN and TITAN studies	9
A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer	9
Identifying and addressing the needs of caregivers of patients with cancer: evidence on interventions and the role of patient advocacy groups	9
Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients	9
Low-Dose Olanzapine, Sedation and Chemotherapy-Induced Nausea and Vomiting: A Prospective Randomized Controlled Study	9
KRAS mutational analysis: a new supplementary diagnostic tool for extrahepatic biliary stenosis	9
Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer	9
A Multicenter, Phase Ib/II, Open-Label Study of Tivozanib with Durvalumab in Advanced Hepatocellular Carcinoma (DEDUCTIVE)	8
INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed/refractory myeloma in routine practice	8
Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design	8
TALAPRO-3 Clinical Trial Protocol: Phase III Study of Talazoparib Plus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer	8
A Real-World US Study of Recurrence Risks using Combined Clinicopathological Features in HR-Positive, HER2-Negative Early Breast Cancer	8
Sacituzumab Govitecan: Past, Present and Future of a New Antibody–Drug Conjugate and Future Horizon	8
Effect of Lateral Lymph Nodes Without Malignant Characteristics on the Prognosis of Patients with Rectal Cancer	8
Efficacy and Safety of Dilpacimab (ABT-165) versus Bevacizumab Plus Folfiri in Metastatic Colorectal Cancer: A Phase II Study	8
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1 -mutant breast cancer during first-line treatment	8
Corrigendum	8
Darolutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer: A Patient Perspective of the ARAMIS Trial	8
Eribulin in Brain Metastases of Breast Cancer: Outcomes of the EBRAIM Prospective Observational Trial	8
The first Middle East and North Africa expert consensus recommendations for management of advanced gastric cancer	8
Real-World Homologous Recombination Repair Mutation Testing in Metastatic Castration-Resistant Prostate Cancer in the USA, Europe and Japan	8
Physician Reported Treatment Patterns and Outcomes in Metastatic Bladder Cancer in the USA: The CancerMPact ^® Survey 2020	8
Phase I Study Protocol: NKTR-255 as Monotherapy or Combined with Daratumumab or Rituximab in Hematologic Malignancies	8
Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol	8
Trastuzumab Deruxtecan for HER2+ Advanced Breast Cancer	8
Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT	8
Corrigendum	8
Corrigendum	8
Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer)	8
ASPiRATION: Australian Observational Cohort Study of Comprehensive Genomic Profiling in Metastatic Lung Cancer Tissue	8
Treatment Patterns and Economic Burden Among Newly Diagnosed Cervical and Endometrial Cancer Patients	8
Diagnostic journey and life impact of cholangiocarcinoma: results from surveys of patient and caregiver experiences	8
Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 study	8
CaboPoint: A Phase II Study of Cabozantinib as Second-Line Treatment in Patients with Metastatic Renal Cell Carcinoma	8
Real-World Outcomes for First Line Next-Generation Hormonal Agents in Metastatic Prostate Cancer: A Systematic Review	8
Olaparib for the Treatment of Metastatic Prostate Cancer	8
Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer	8
BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors	8
The Genetic Polymorphisms in the SP4 Gene and the Risk of Gastric Cancer	7
A comparison of anticholinergic burden in older patients with and without cancer	7
Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TAL	7
Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey	7
Plain language summary of isatuximab plus carfilzomib, lenalidomide, and dexamethasone for the treatment of people with high-risk newly diagnosed multiple myeloma	7
Correction	7
Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)	7
Uncommon EGFR Mutations Conducted with Osimertinib in Patients with NSCLC: A Study Protocol of Phase 2 Study (UNICORN/TCOG1901)	7
Effect of multidisciplinary team-style continuity of care and nutritional nursing on lung cancer: randomized study	7
Real-World Treatment of Patients with Palbociclib for HR+/HER2-Advanced/Metastatic Breast Cancer: The Europe IRIS Study	7
Risk of Toxicity with Immunotherapy–Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma: A Meta-Analysis of Randomized Controlled Trials	7
Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003	7
A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera	7
Decoding clinical trial jargon: helping people understand the efficacy end points used in cancer trials	7
Treatment of the blood cancer polycythemia vera with ruxolitinib in the MAJIC-PV study: a plain language summary	7
CASE (CemiplimAb-rwlc Survivorship and Epidemiology): a study in advanced basal cell carcinoma	7
Diagnosis, treatment and burden in advanced ovarian cancer: a UK real-world survey of healthcare professionals and patients	7
The treatment of advanced pulmonary sarcomatoid carcinoma	7
Molecular Methods for Increasing the Effectiveness of Ovarian Cancer Treatment: A Systematic Review	7
Low Expression of TFF3 in Papillary Thyroid Carcinoma may Correlate with Poor Prognosis but High Immune Cell Infiltration	7
Prognostic Implication of Serum AFP in Patients with Hepatocellular Carcinoma Treated with Regorafenib	7
Prognostic Significance of Hemoglobin-To-Red Cell Distribution Width Ratio in Patients with Metastatic Renal Cancer	7
Increased Cytoplasmic Expression of DLL4 is Associated with Favorable Prognosis in Colorectal Cancer	7
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer	7
Genetic variants in mitochondrial sirtuins associated with brain tumor risk: a case–control study	7
Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?	7
Levetiracetam and valproic acid in glioma: antiseizure and potential antineoplastic effects	7
The burden of ovarian cancer in the USA from 2007 to 2018: evidence from the Medical Expenditure Panel Survey	7
Molecular and Morphological Changes Induced by Ivosidenib Correlate with Efficacy in Mutant- IDH1 Cholangiocarcinoma	7
Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer	7
Statins increase pathological response in locally advanced rectal cancer treated with chemoradiation: a multicenter experience	7
A Phase II Study of Perioperative Treatment in Gastric Cancer with No.16a2/b1 Lymph Node Metastasis: DRAGON-06 Trial	6
Treatment Patterns and Overall Survival in HER2+ Metastatic Breast Cancer at US Community Oncology Practices	6
Metastatic non-small-cell lung cancer without driver mutations: projections by therapy line in Western Europe, 2021–2026	6
Circulating microRNAs as Potential Biomarkers in Triple-Negative Breast Cancer: A Translational Research Study of the NACATRINE Trial	6